Status:
COMPLETED
Burden of Illness and Treatment Assessment of Patients With Dry Eye Disease: A Cross-Sectional Survey of Real-World Patients With Dry Eye Disease in the US
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Dry Eye Disease
Eligibility:
All Genders
18+ years
Brief Summary
This study employed secondary database analysis of the Adelphi Dry Eye Disease (DED) Disease Specific Programme™ (DSP™), a templatized cross-sectional survey with retrospective data collection that is...
Eligibility Criteria
Inclusion
- Main Sample:
- ≥ 18 years of age.
- Physician-confirmed DED diagnosis (at time of data collection).
- Xiidra® Oversample:
- ≥ 18 years of age.
- Physician-confirmed DED diagnosis (at time of data collection).
- Have a current prescription for Xiidra® for their DED (at time of data collection).
Exclusion
- Main Sample:
- • Involved in a DED clinical trial (at time of data collection).
- Xiidra® Oversample:
- Involved in a DED clinical trial (at time of data collection).
- Included in the main sample previously.
Key Trial Info
Start Date :
June 2 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 19 2022
Estimated Enrollment :
946 Patients enrolled
Trial Details
Trial ID
NCT06018571
Start Date
June 2 2022
End Date
August 19 2022
Last Update
August 30 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis
East Hanover, New Jersey, United States, 07936